FDA Classifies Continuous Glucose Monitor Retrospective Data Analysis Software as Class I, 510(k) Exempt Medical Device

September 20, 2026

FDA.gov USA

Overview

The U.S. FDA has classified continuous glucose monitor retrospective data analysis software (Product Code PHV) as a Class I medical device, exempting it from 510(k) premarket notification. This software is intended to analyze and correlate historical data from continuous glucose monitoring devices. This classification clarifies regulatory requirements for such data management systems, enabling developers to bring products to market more quickly and supporting improved diabetes care.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has officially classified continuous glucose monitor (CGM) retrospective data analysis software as a Class I medical device, exempting it from the 510(k) premarket notification process. This action simplifies the development and market entry of CGM data management and analysis tools, indirectly supporting improved care for individuals with diabetes.

Technical / Clinical Details

The software categorized under this classification (Product Code PHV) primarily functions to analyze and correlate historical glucose data, trends, and patterns collected by continuous glucose monitoring devices. It is not intended for real-time therapeutic decision-making but rather provides supplementary information for healthcare professionals to assess a patient’s long-term glycemic control and consider adjustments to treatment strategies. The Class I classification indicates that the FDA deems this type of software to pose a low risk to patients. The 510(k) exemption allows developers to bypass the premarket notification process, enabling quicker market access for their products. For instance, this software can calculate and graph metrics such as average glucose, variability, Time-in-Range (TIR), and Time-Below-Range (TAR), assisting clinicians in optimizing diabetes management.

Background & Context

With the widespread adoption of CGM technology, vast amounts of glucose data are being generated. The importance of software tools to effectively analyze this data and derive clinically meaningful insights has grown significantly. The FDA’s classification and exemption clarify the regulatory pathway for digital healthcare solutions, particularly data analysis and management tools. This is expected to accelerate innovation, making it easier for more companies to develop solutions that meet the needs of both patients and healthcare professionals. This move is closely linked to the evolution of digital biomarkers and AI-driven analytics, contributing to the advancement of personalized diabetes management.

Strategic Significance & Outlook

The regulatory clarification for continuous glucose monitor retrospective data analysis software will have a positive impact on the entire diabetes management ecosystem. Developers can bring their products to market more rapidly and efficiently, while healthcare professionals can gain deeper insights into patient data to make more informed decisions. In the future, it is anticipated that such software will integrate with AI and machine learning to enable more advanced predictive analytics and personalized treatment recommendations. This will play a crucial role in enhancing patient self-management capabilities and reducing the risk of diabetes complications.

Source: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=PHV

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.